Complaint
| Product Name | CAS 518048-05-0 hrk High Quality Raltegravir Powder |
| CAS | 518048-05-0 |
| Appearance | white powder |
| Molecular formula | C20H21FN6O5 |
| Molecular Weight | N/A |
| Assay | 98% |
| Shelf Life | 24 months when properly stored |
| Storage | Keep in a cool, dry, dark location |
What is Raltegravir?The Merck's ray rutgers piece is the first integrated polymerase chain transfer HIV inhibitors (English integrasestrandtransferinhibitors, referred to as integrase inhibitors), also called MK - 0518, Human immunodeficiency virus (HIV)-1 infection can be treated in combination with other antiretroviral drugs. It slows the development of HIV-1 infection by inhibiting the HIV integrase needed for viral replication. Pharmacological action When combined with other anti-HIV drugs, Retegvir reduces the amount of HIV in the blood and increases the number of white blood cells called CD4+T cells, which help fight other infections. Studies on the interaction with Ritonavir, Faeveram, Teranavir, Tenofovir, etc., showed that this product had no cross-resistance with anti-drugs, and had synergistic effects with a variety of drugs. |
Raltegravir ,It can be combined with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) -1 infection. It slows down HIV-1 infection by inhibiting the HIV integrase required for viral replication. When Rett Kawet with other anti HIV drugs can reduce the number of HIV in blood, and the increase of CD4+T cells known as the number of white blood cells, contribute to the anti infection. Show with Lito Bernard Vee, efavirenz, tenofovir for Ranave, the interaction of the goods and drug resistance no cross resistance and has a synergistic effect with multiple drugs.
Raltegravir (RAL), , used to treat HIV infection.
In a study of the drug as part of combination therapy, raltegravir exhibited potent and durable antiretroviral activity similar to that of efavirenz at 24 and 48 weeks but achieved HIV-1 RNA levels below detection at a more rapid rate. After 24 and 48 weeks of treatment, raltegravir did not result in increased serum levels of total cholesterol, low-density lipoprotein cholesterol, or triglycerides
Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN.
Company Information
Our Certificate
Our Service
Our Research
Packaging & Logistics
